Sophiris Bio Inc.'s shares (NASDAQ:SPHS) rose 69.2 percent to a $1.98 close on Friday after publishing data showing that a single injection of PRX302 (topsalysin) durably destroyed localized prostate cancer tumor cells in half of the 18 men enrolled in an open-label phase IIa study.